Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin: Letter to the editor

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 3, 2008, Pages 1063-1065

  Zauli, Giorgio ^a   Rimondi, Erika ^a   Secchiero, Paola ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; DRUG INTERACTION; GENETICS; HUMAN; LETTER; METABOLISM; MONONUCLEAR CELL; OSTEOCLAST; PHYSIOLOGY; SOLUBILITY; TIME;

CELL DIFFERENTIATION; CELLS, CULTURED; DRUG INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECOMBINANT PROTEINS; SOLUBILITY; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 44149085663     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00265.x     Document Type: Letter

References (16)

1. Boyle WJ, Scott SW, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 423 : 337 42.
2. Zauli G, Secchiero P. 2006 The role of theTRAIL-TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006 17 : 245 57.
3. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McMaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML. Temperature-sensitive differential affinity of TRAIL for its receptors. J Biol Chem. 2000 275 : 23319 25.
4. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and RANKL or TRAIL: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007 282 : 31601 9.
5. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003 63 : 912 6.
6. Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res. 2004 19 : 1712 21.
7. Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006 42 : 415 20.
8. Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, Kamachi M, Ida H, Migita K, Origuchi T, Nakao K, Eguchi K. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol. 2004 137 : 430 6.
9. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Icone A, Zauli G. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood. 2004 103 : 517 22.
10. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002 100 : 2421 9.
11. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis inducing lig-and (TRAIL) blocks osteoclastic differentiation induced by RANKL+M-CSF. Blood. 2004 104 : 2044 50.
12. Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun. 2005 333 : 42 50.
13. Colucci S, Brunetti G, Cantore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis. 2007 12 : 1623 32.
14. Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol. 2008 214 : 117 25.
15. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG-TRAIL interaction. Blood. 2004 104 : 3722 30.
16. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P. Tumor necrosis factor-related apopto-sis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003 92 : 732 40.